New to Insight Pharma Reports is Vaccines: The End of Illness. This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.
Specific Highlights Include:
This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies – including 35 small pharma companies and 8 big pharma companies profiled
The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
Survey of industry experts concerning the political economic and technological future of vaccine technology.
Over 20 pages of pipeline and clinical trial data specific to vaccine targets
Over 30 pages of pipeline and clinical trial data specific to cancer vaccines
- Table of Contents
Chapter 1: Introduction
1.1 The History of Vaccination
1.1.2. 18th century
1.1.3. 19th century
126.96.36.199. Coley’s toxins
1.1.4. Mid 20th century
1.2. Vaccines in the Doldrums: late 20th century
1.2.1. Liability issues
1.2.2. Vaccine denialism
1.3. The Current State of Vaccine technology, 2013
1.3.2. Behemoth players: Bill and Melinda Gates
1.3.3. Big pharma jumps in
Chapter 2: A Cornucopia of Vaccine Technologies
2.1. Vaccine production: eggs versus cell culture
2.2. Cell line options
2.3 Conventional Vaccines
2.5. Nanoparticle-based vaccines
2.6. DNA Vaccines
2.7. Vaccines driving T-cell activation
2.8. Dendritic cells
Chapter 3: Vaccine Targets
3.1. Infectious Diseases
3.1.2. HSV A & B
3.1.3. C. difficile
3.1.12. Parasitic diseases
3.2. Cancer vaccines
3.2.1. Human papilloma virus
3.2.2. Breast cancer
3.2.3. Pancreatic cancer
3.2.4. Renal cell carcinoma
3.2.5. Melanoma: dendritic cells
3.2.6. Prostate cancer
Chapter 4: Big Pharma Vaccines
4.1. AstraZeneca (Medimmune)
4.4. J&J (Crucel)
Chapter 5: Small Pharma Vaccines
5.1. AC Immune
5.6. Bavarian Nordic
5.7. BiondVax Pharmaceuticals
5.8. Braasch Biotech LLC
5.11. Emergent Biosolutions
5.15. Genocea Biosciences
5.16. Immune Targeting Systems
5.17. Indian Immunologicals Limited
5.20. Juvaris Biotherapeutics
5.27. Profectus Bioscience Inc
5.29. Sorrento Therapeutics, Inc.
5.34. VBI vaccines
Chapter 6: Regulatory Issues
6.1. A bumpy road
6.2. Current regulatory status
Chapter 7:The Future of Vaccine technology
7.1. Challenges in delivery and storage
7.2. Dry vaccine technology: Ready for prime time?
7.3. A universal Vaccine
7.4. Outlandish targets
7.4.1. Drug abuse
7.4.5. Alzheimer’s disease
7.4.6. Parkinson’s Disease
7.5. Bioterrorism: A global threat?
7.6. Intellectual Property in the Balance
7.7. A bright future for Vaccines
- List of Figures
Figure 1.1: Overall Decline in Worldwide Death Rates
Figure 2.5: Application of Nano-Sized Delivery Systems
Figure 5.11: Emergent’s ADAPTIR Design Technology for Antibody Therapeutics
Figure 5.15: Genocea Technology for Screening Candidate Vaccines Components
Figure 6.2: Development of Anti-cancer Vaccine Products and the Regulatory Guidance Throughout the Process
Figure 8.1: Makeup of the Participants in the Survey
Figure 8.2: Breakdown of Opinions of the Industrial Commitment of Resources
Figure 8.3: How Should the Industry Focus its R&D Efforts in Vaccine Technology?
Figure 8.4: What are the Most Promising Cancer Vaccine Targets?
Figure 8.5: How Seriously are the Federal Governmental Bodies Committed to Vaccine Technology?
Figure 8.6: State and Local Governmental Support for R&D. How Does it Stack Up?
Figure 8.7: The Softest Cancer Vaccine Target
Figure 8.8: Where is the Vaccine Market Headed?
Figure 8.9: Why Would a Vaccine Development Program be Vetoed?
Figure 8.10: The Fallout from Vaccine Denialism
Figure 8.11: Where is Bioprocessing of Vaccines Headed?
Figure 8.12: Cancer Vaccines: Still a Long Ways Off
Figure 8.13: AIDS Vaccines: Further Down the Road than Cancer Vaccines?
Figure 8.14: The Road Ahead: Daunting Challenges
Figure 8.15: Is Regulatory Control of Vaccines a Problem?
Figure 8.16: How Does the Industry Feel About Vaccines as a Barrier to Terroristic Threats?
Figure 8.17: When Vaccines Fail
Figure 8.18: Bioinformatics: A Pathway to Innovative Vaccine Antigens
Figure 8.19: Counteracting Vaccine Denialism
Figure 8.20: Opinions on the Rise of Therapeutic Vaccines
Figure 8.21: The Future of Oral Vaccines
Figure 8.22: Vaccine Technology in the Third World
Figure 8.23: Vaccines and the Battle Against Hepatitis C
Figure 8.24: Academic/Industrial Partnerships: Do They Have a Future?
Figure 8.25: Alternative Pathways Toward Speeding Vaccine Development
Figure 8.26: A New Look at DNA Vaccines
- List of Tables
Table 2.2: Anti-Viral Vero Cell-Based Vaccines
- Companies Covered